Fig. 3
From: Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Common CAR-T cell therapy targets in solid tumors. EGFR: epidermal growth factor receptor; GD2: ganglioside2; MUC1: mucin 1; NKG2DL: natural killer group 2 member D ligand; HER2: human epidermal growth factor receptor 2; HNSCC: head and neck squamous cell carcinoma; TC: thyroid cancer; ICAM-1: intercellular adhesion molecule-1; LCa: lung cancer; PD-L1: programmed death-ligand 1; MSLN: mesothelin; ROR: receptor tyrosine kinase like orphan receptor; CEA: carcinoembryonic antigen; NY-ESO-1: New York esophageal squamous cell carcinoma-1; DLL3: delta-like ligand 3; BC: breast cancer; OS: osteosarcoma; EWS: Ewing’s sarcoma; MEL: melanoma; VEGFR-2: vascular endothelial growth factor receptor 2; RCC: renal cell carcinoma; CAIX: carbonic anhydrase IX; GPC3: glypican-3; OC: ovarian cancer; CC: cervical cancer; ALPPL2: alkaline phosphatase placental-like 2; PCa: prostate cancer; PSMA: prostate-specific membrane antigen; PSCA: prostate stem cell antigen; CRC: colorectal cancer; PC: pancreatic cancer; CLDN: claudin; GC: gastric cancer; GUCY2C: Guanylyl cyclase C; HCC: hepatocellular carcinoma; EC: esophageal cancer